8月11日盘后,恒瑞医药(SH600276,股价54.97元,市值3635.26亿元)连发两则公告,宣布公司及子公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,两款自主研发的创新药获批开展临床试验,研发管线再添新进展。其中一款为针对2型糖尿病的多肽类三靶点激动剂,另一款为针对炎症性肠病的治疗用生物制品,两者在全球范围内均尚无同类药物获批上市。 两款创新药获批开展临床试验 根据...
Source Link8月11日盘后,恒瑞医药(SH600276,股价54.97元,市值3635.26亿元)连发两则公告,宣布公司及子公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,两款自主研发的创新药获批开展临床试验,研发管线再添新进展。其中一款为针对2型糖尿病的多肽类三靶点激动剂,另一款为针对炎症性肠病的治疗用生物制品,两者在全球范围内均尚无同类药物获批上市。 两款创新药获批开展临床试验 根据...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.